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Abstract
This case report addresses diabetic peripheral neuropathic pain (DPNP), a chronic condition
associated with diabetes mellitus. There are over 29 million people in the United States who have
diabetes (Diabetes latest, 2014). About 25% of diabetics have pain from diabetic peripheral
neuropathy (Snyder, Gibbs , & Lindsay, 2016). This is a very challenging and difficult condition
to treat as it can negatively affect a person’s quality of life. This case report is based on a patient
encounter. This is a patient who currently has diabetes, but has not been diagnosed with DPNP. I
will examine two different treatment approaches for DPNP, pregabalin and duloxetine, and how
effective they are in managing that pain. Pregabalin is classified as an anti-convulsant.
Duloxetine is a serotonin norepinephrine reuptake inhibitor. Ten research articles were reviewed
that compare the use of pregabalin and/or duloxetine in the treatment of neuropathic pain. They
included 4 randomized clinical trials (RCTs), a meta-analysis, a systematic review, a
retrospective chart review, a retrospective review of insurance claims, and two prospective
studies. In every study, it was found that both duloxetine and pregabalin are effective in treating
DPNP. However, there were contradictory findings related to the superiority of one over another.
In one study duloxetine, did not have a direct comparison and in another pregabalin was
compared to placebo. Three of the studies reported duloxetine superior to pregabalin. In one of
these studies, the recommended effective dosage of pregabalin was not always given. One study
found pregabalin superior to duloxetine. Another showed suboptimal dose of duloxetine
compared to pregabalin. There were also four studies that included gabapentin alone or in
combination as a treatment comparison for duloxetine and pregabalin. Side effects are common
with both medications and one study showed more minor side effects with duloxetine. Pregabalin
was found to have a secondary improvement in sleep. Quality evidence was found supporting the
use of pregabalin and duloxetine for effective DPNP treatment.
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Background
Millions of people throughout the world are affected by the chronic disease Diabetes
Mellitus. It is characterized by a resistance to insulin action, inadequate disseminating
endogenous insulin, and an insufficient compensatory insulin secretion reaction (Dunphy,
Winland-Brown, Porter, & Thomas, 2015). Diabetes causes long-term damage and many comorbidities due to chronic hyperglycemia. This can affect a person’s eyes, heart, blood vessels,
nerves, and kidneys. Macrovascular and microvascular damage is associated with long-term
hyperglycemia. “Vascular endothelial dysfunction and inflammation result in fibrosis and intimal
thickening, leading to progressive narrowing of the vascular lumen” (Dunphy, Winland-Brown,
Porter, & Thomas, 2015, p. 891). This results in ischemia throughout the body due to reduced
blood flow through the microvasculature. Common symptoms that are associated with diabetic
peripheral neuropathy are pain, burning, allodynia, paresthesia, and hyperalgesia.
The purpose of this report is to address the pain and discomfort associated with peripheral
neuropathy by examining two treatment options that are approved by the United States Food and
Drug Administration (FDA) for treating diabetic peripheral neuropathic pain. These treatment
options are duloxetine and pregabalin. The mechanism of action of pregabalin, an
anticonvulsant, includes attaching to the α2-δ subunit of calcium channels in afferent neurons.
This action decreases the release of substance P, glutamate and norepinephrine. By doing this, it
decreases pain signals that are transmitted to the brain. Duloxetine, an antidepressant, has a
mechanism of action that involves obstructing the reuptake of norepinephrine and serotonin in
the central nervous system. By doing this it reduces the awareness of pain by lessening pain
signals (Tanenberg, et al., 2011). There is an additional medication called tapentadol that is also
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approved by the FDA for severe diabetic neuropathic pain that will not be addressed in this case
report.
Diabetic peripheral neuropathy and the pain associated with it is a manifestation of the
reduced blood flow and inflammation to the microvasculature. This condition is more common
in patients with low glycemic control and low serum insulin concentrations. The occurrence
increases over time with diabetes. The patient may also experience a loss of sensation and
muscle weakness. The pain associated with peripheral neuropathy can lead to mood and sleep
disorders (Dunphy, Winland-Brown, Porter, & Thomas, 2015).
The following case provides the background for this case report. This is a 60-year-old
woman who has had diabetes type 2 for 10 years. Although she did not present with any
peripheral neuropathy, the likelihood of developing this increases with time and having
persistent hyperglycemia. The management of blood sugars is crucial with this type of patient
and can prevent further disability down the road. By looking at what treatments and dosages are
effective for DPNP, we can use this information to successfully treat difficult to manage chronic
pain instead of experimenting with different treatments that are ultimately ineffective.
Case Report
Dorothea 60-year-old female
CC: Diabetes recheck
HPI: 60-year-old white female presents to the clinic today for a diabetes check-up. She was
diagnosed with diabetes 10 years ago and has been on Metformin since her diagnosis. She states
her diabetes is under good control and she checks her blood sugar a couple times a week and it
usually runs in the 150-200 range. She saw the diabetes educator last week and was told she
needed to eat better and incorporate more fruits and vegetables in her diet. She reports liking
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sweets a lot and knows she eats too many. She also drinks three beers two to three times a week.
She reports walking a mile a day for exercise. The only concern she has today is that she has
been feeling more tired the last few months. She hasn’t had any recent changes to her schedule.
She works full-time as an information specialist at the University of North Dakota. She states she
has been sleeping ok and getting around eight hours of sleep at night. She denies having her
thyroid or TSH level checked in the past.
Medications:
Metformin 500 mg po twice daily
Aspirin 81 mg po daily
Lisinopril 20 mg po once daily
Atorvastatin 20 mg po once daily
Multivitamin 1 tablet po once daily
PMH:
Diabetes
Hypertension
Dyslipidemia
Surgeries:
none
Review of Systems:
Constitutional: No weakness, fever or night sweats
Eyes: Patient wears glasses. She reports no blurred vision, eye pain, redness, itching, tearing,
diplopia, flashers, floaters or light sensitivity. Last eye exam was 6 months ago.
Ears: Reports no hearing loss, pain, discharge, tinnitus, vertigo, or fullness
Nose: Reports no congestion, epistaxis, postnasal drip, sinus pain or pressure.
Mouth and Throat: Reports no recent dental problems. Last saw dentist in 2016. Denies
hoarseness, sore throat, dryness, bleeding gums or lesions.
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Head & Neck: Reports no headaches, syncope, swollen glands, pain or neck stiffness
Respiratory: Reports no SOB, wheezing, cough, or hemoptysis
CV: Reports no chest pain or tightness, palpitations, edema, diaphoresis, dizziness, or orthopnea.
Denies leg cramps or intermittent claudication.
GI: Reports no abdominal pain, bloating, or cramping. Denies dysphagia, heartburn, dyspepsia,
N/V, diarrhea, constipation. No blood in stool or black, tarry stool.
GU: Denies vaginal itch, lesions. Reports no dysuria, urgency, frequency or hematuria.
MS: No joint pain or stiffness. No swelling or motion restriction. No muscle pain.
Neuro: No numbness or tingling to upper or lower extremities.
Objective:
VS: BP-148/98, P-80, RR-20, T-98.6
Labs:
HgbA1C- 8.5%
Lipid panel: Cholesterol-209, LDL- 120, Triglycerides-185, HDL-33
CMP- Normal
TSH- Normal
Diabetic foot exam: Sensation normal. Feet warm and dry. No open lesions or calluses present.
General: Well -developed 60-year-old white female appearing stated age. In no acute distress.
Alert and cooperative with exam.
Head: Normocephalic and atraumatic without scalp or facial tenderness.
Eyes: Conjunctivae are pink and sclera are without injection or jaundice.
Ears: TMs shiny and pearly gray with bony landmarks and cone of light visible. No perforations
or bulging. Canals without erythema, lesions, or excessive cerumen. Hearing grossly intact.
Mouth: Teeth in good repair. No lesions or exudates in oropharynx or oral mucosa. Uvula rises
midline with phonation.
Neck: Trachea midline, thyroid not palpable. No cervical, submandibular, submental, pre-or
post-auricular lymph nodes appreciated. Flexion, extension, and rotation without hesitation or
limitation.
Chest: Breath sounds clear throughout lung fields without rales, rhonchi, wheezes, or stridor
CV: S1S2 with regular rate and rhythm. No S3, S4, murmurs, clicks or rubs
Abdomen: Non-distended. No tenderness to palpation. Bowel sounds present all 4 quadrants.
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MS: Full ROM to all joints without hesitation, pain, clicking, or limitation.
Skin: Warm and dry. No rashes or lesions
Neuro: Speech fluent. Mood euthymic with affect appropriate to situation.
Assessment:
Diabetes Mellitus type 2
Dyslipidemia
HTN
Plan:
1. Increase Metformin 1000 mg po twice daily.
2. Discussed with patient that the goal is to get her HgbA1C down to < 6.0%. We will
recheck her HgbA1C in 3 months. Patient is encouraged to reduce her intake of sweets
and eat more fruits and vegetables and follow the recommendations from the diabetic
educator. She is encouraged to keep exercising daily. Patient is agreeable to this.
3. Lisinopril/Hydrochlorothiazide (HCTZ) 20 mg/12.5 mg po once daily.
4. Discussed with patient that I would like her to purchase a blood pressure monitor and
check her BP a couple of times a week and record. Then follow-up with me in 1 month to
reassess if we can continue with the current blood pressure medication or if we need to
add on a second medication. Patient is agreeable to this.
5. Increase Atorvastatin 40 mg po once daily. Discussed with patient that her Triglycerides
are still elevated and her HDL is lower than what I would like it to be. Hopefully with her
diet changes and increased medication this will improve. We will recheck her Lipids at
her 3-month follow-up.
6. Patient is to return to the clinic or follow-up sooner than 1 month with any other
questions or concerns.
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Literature Review
The following is a review of the current literature related to the efficacy of treatment for
DPNP with the medications pregabalin and duloxetine in adult patients. Pregabalin and
duloxetine are currently two of three medications approved for treatment of DPNP by the FDA.
The third medication is tapentadol extended release for severe DPNP. Pregabalin is classified as
an anti-convulsant and is indicated for neuropathic pain, fibromyalgia, and post-herpetic
neuralgia. Duloxetine is classified as a serotonin-norepinephrine reuptake inhibitor and is
indicated for depression, generalized anxiety disorder, fibromyalgia, musculoskeletal pain, and
neuropathic pain. There have been numerous clinical trials examining the effectiveness of
pregabalin and duloxetine for treating DPNP. Some of these studies included additional
medications as comparisons. Gabapentin is one of those medications along with amitriptyline.
Lunn, Hughes, and Wiffen conducted a systematic review that looked specifically at
duloxetine for treating neuropathic pain, in addition to fibromyalgia and chronic pain. Eighteen
trials with a total of 6407 participants were identified. They reviewed eight published studies
with 2728 adult patients with diabetic neuropathic pain (2014). They found that there was
moderate quality of evidence that the use of duloxetine in daily dosages of 60 mg and 120 mg
were effective for treating painful diabetic peripheral neuropathy (PDPN). However, lower
dosages were not effective. The review also concluded that minor side effects were common
with the duloxetine dosages of 60 mg and more specifically with the 120-mg dosage. These
minor side effects included headache, dry mouth, feeling sick, too sleepy or too awake,
dizziness, and constipation. One out of 6 people discontinued duloxetine due to side effects.
(Lunn, Hughes, & Wiffen, 2014).
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Three randomized, double-blind and comparable 13-16 week trials were conducted to
determine pregabalin efficacy in treating diabetic peripheral neuropathy (DPN), post-herpetic
neuralgia, and spinal cord injury. The randomized control trials (RCTs) included a 52-week
expansion trial. Participants in the DPN RCT received dosages of either 300 mg or 600 mg a day
or a placebo. This was administered over twelve weeks after a week of titration. The patients
selected had moderate to severe pain with a chronic, unrelenting neuropathic pain (Ogawa,
Arakawa, Hayakawa, & Yoshiyama, 2016). They found considerable pain improvement after
one week. This improvement lasted the extent of the trial. It was concluded that in treating
central and neuropathic pain, pregabalin was repeatedly effective. Additionally, it was found
that pregabalin improved sleep disorder scores compared to the placebo after one week. They
also found that in the peripheral pain trials, patients that withdrew from the trial due to side
effects related to treatment was somewhat higher than in the comparable studies. This was
attributed to the two different dosage regimens.
A retrospective analysis done by Yang, Qian, and Liu studied health insurance claims
from 2006-2011 in the United States to further examine DPNP treatment models. Out of the
12,074 patients, 21.6% were given pregabalin, 45% were given gabapentin and 5.2% started
duloxetine. There were also 20 patients that were prescribed a combination of duloxetine and
pregabalin. The recommended doses per the FDA are up to 300 mg a day for pregabalin and 60
mg a day for duloxetine. “More than 60% of duloxetine-treated patients were receiving the
recommended dose, although 31.0% were receiving just 30 mg/day. Patients treated with
pregabalin (91.3%) received less than 300 mg/day” (Yang, Qian, & Liu, 2015, p. 2079). Often,
patients received less than the recommended dosage. Of the patients that received pregabalin,
55% received 150 mg/day and sometimes even lower dosages. This despite clinical evidence
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showing that dosages this low are comparable to receiving a placebo and do nothing for
symptom control. Anticonvulsants are the most frequently prescribed medications for DPNP for
those patients that are newly diagnosed, however these medications were often discontinued
early. It was also found that within three months of medication initiation, 50% of patients
discontinued their prescription. The one-year discontinuation rates for duloxetine-64.4%, and
pregabalin-76.7% (Yang, Qian, & Liu, 2015).
A prospective observational 6-month study that included 2575 patients examined the
effectiveness of pregabalin, duloxetine and gabapentin on DPNP (Happich, et al., 2014). They
found that younger patients switched to or started duloxetine. These patients also worked for pay
more often and had higher alcohol intake. They were more often receiving treatment from a
general practitioner and not a neurologist. They more frequently had depression and type 2
diabetes. They had previous treatment with other antidepressants, non-opioid analgesics and
opioids. They also had more disease-related problems, more severe pain, and poor mental health.
They found that patients treated with pregabalin and gabapentin were not treated with
appropriate dosages. This could explain the outcomes of the study, that patients treated with
duloxetine showed substantially superior improvements in efficacy measures than those treated
with gabapentin or pregabalin. The duloxetine patients often received recommended dosages
with an average daily dosage of 53.9 mg. The average daily dosage of pregabalin was 173.5 mg
(Happich, et al., 2014). This contrasted with the previous study from Yang et. al. that showed
suboptimal dosages of duloxetine were used for treating DPNP (2015).
A prospective 6-month study done by Roy et al., not only compared the efficacy of
duloxetine and pregabalin, but also examined the cost effectiveness of both medications for
treating DPNP. The study was conducted in a diabetic clinic in South India. The patients were
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not previously treated with either drug. Fifty patients were treated with pregabalin and 50
patients were treated with duloxetine. The Neuropathic Pain Scale and the Neuro-Qol
questionnaires were used to assess patient’s pain. In treating neuropathic pain, duloxetine was
found to be more effective than pregabalin, but was more expensive. However, both medications
were shown to significantly reduce DPNP. Fourteen patients dropped out that were taking
duloxetine and 2 that were taking pregabalin. The discontinuation was due to a combination of
adverse events, cost, alternative therapy, and termination of treatment (Roy, Kuriakose, Varma,
& Jacob, 2017).
A double-blind RCT done by Boyle et al. (2012), examined the pain-relieving efficacy of
duloxetine, pregabalin, and amitriptyline along with their secondary effect on sleep, quality of
life and daytime functioning in patients with DPNP. This secondary effect on mood and sleep
may play a part in the successful treatment of patients with DPNP. Between February 2007 and
March 2009, 83 subjects with diabetes type 1 and 2 participated in the study. Twenty-seven were
given pregabalin, 28 amitriptyline, and 28 duloxetine. When compared with placebo, pregabalin,
duloxetine and amitriptyline all reduced pain with not one medication better than another. There
was a 50% improvement in subjective pain which is comparable to similar studies. As far as
sleep continuity, there was a pronounced reduction in REM sleep and sleep was very disjointed
with duloxetine, but duloxetine did improve performance on sensory motor tasks and improved
central nervous system stimulation (Boyle, et al., 2012). Whereas, pregabalin stimulated sleep.
As far as medication effects on daytime activity function, it was comparatively ineffective. A
higher number of side effects also were found in the subjects treated with pregabalin.
One RCT examined patients that were originally treated with gabapentin >= 900 mg/day
for DPNP and had an unsatisfactory response with a pain score >=4 using a 0-10 pain scale.
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These patients were then randomized to be treated with either pregabalin (n=134), duloxetine
(n=138), or a combination of gabapentin and duloxetine (n=135). The purpose of this study was
to determine if treatment with duloxetine was substandard in comparison to treatment with
pregabalin. The duloxetine dosage was titrated up to 60 mg/day after one week. The pregabalin
dosage was titrated up to 300 mg/day after one week. The third group treated with a combination
of gabapentin/duloxetine remained on the initial dosage of gabapentin >=900 mg/day in addition
to titrating the dosage of duloxetine up to 60 mg/day. Researchers reported that considerably
more patients discontinued the duloxetine (n=27) due to side effects than with the pregabalin or
the gabapentin/duloxetine combination. These side effects included, nausea, decreased appetite,
excessive perspiration, and insomnia. However, peripheral edema was greater with the use of
pregabalin. Researchers concluded that treatment with duloxetine was non-inferior to pregabalin
and gabapentin/duloxetine for DPNP. They also found that adding duloxetine to the gabapentin
was effective in treating DPNP similar to using pregabalin or duloxetine alone. (Tanenberg, et
al., 2011).
A randomized, double-blind COMBO-DN study examined the Neuropathic Pain
Symptom Inventory (NPSI) of patients initially to determine a baseline, then after either
pregabalin or duloxetine therapy for eight weeks, and then again after an eight-week increased
dose/combination therapy. The study also showed that diabetic patients present with differing
sensory profiles in their response to pain. The initial therapy was 300 mg pregabalin or 60 mg
duloxetine. If patients had <30% improvement, then the patients receiving duloxetine, increased
to 120 mg and patients receiving pregabalin increased to 600 mg or a combination of 300 mg
pregabalin and 60 mg duloxetine. In the primary therapy duloxetine worked better for pain. “The
present exploratory analyses of data collected in the COMBO-DN study suggest that duloxetine
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and pregabalin have different effects on distinct neuropathic pain components in diabetic
peripheral neuropathy” (Bouhassira, et al., 2014, p. 2174). In patients not responding to the
initial monotherapy of duloxetine, the combination of duloxetine and pregabalin was favorable in
patients with persistent and induced pain. In patients where dysesthesia/paresthesia is
pronounced, increasing the duloxetine to 120 mg/day was more advantageous (Bouhassira, et al.,
2014).
A meta-analysis was used to examine the tolerability and effectiveness of duloxetine to
pregabalin and gabapentin compared with a placebo in treating DPNP. A total of eleven RCTs
were reviewed, with 3 studies on duloxetine, 6 on pregabalin, and 2 on gabapentin. A 24-hour
average pain severity was used to assess treatment effectiveness. Duloxetine, pregabalin and
gabapentin were found to be exceptional compared to the placebo. Duloxetine was associated
with more incidences of nausea, headache, dizziness, and sleepiness. It also had greater
occurrences of discontinuation compared to placebo. This was a similar case with pregabalin.
Pregabalin was associated with somnolescence and dizziness along with greater discontinuation
compared to placebo. In the direct comparison of pregabalin and duloxetine, three effectiveness
outcomes were considered; seven tolerability outcomes, 24-hour pain severity, and Patient
Global Impression of Improvement/Change (PGI-I/C). There was found to be no difference in
24-hour PS between pregabalin and duloxetine. It was found that the PGI-I/C was preferential to
pregabalin, and duloxetine was preferred in the tolerability outcomes (Quilici, et al., 2009).
A retrospective chart review done in a neuromuscular outpatient clinic examined the use
of duloxetine and pregabalin for diabetic neuropathic pain (DNP) over a 10-month period. In
addition, the chart review examined the effect of these two medications on cryptogenic sensory
polyneuropathy. This is a common type of neuropathy seen in patients over 50 years of age. One

EFFECTIVENESS OF DULOXETINE AND PREGABALIN IN DIABETIC

15

hundred and three patients were started on duloxetine and 91 patients were started on pregabalin.
Those patients taking pregabalin (33%) conveyed a greater improvement in neuropathic pain
compared to the patients taking duloxetine (21%). Compared to pregabalin (30%), duloxetine
(38%) had more reported side effects. There were no significant differences between duloxetine
and gabapentin. This retrospective review suggests that duloxetine and pregabalin would both be
effective in treating DPN secondary to either cryptogenic sensory polyneuropathy or diabetes
mellitus. (Mittal, et al., 2011).

Learning Points
When using the recommended doses of pregabalin and duloxetine, both are very effective
medications to use for DPNP. However, when providers prescribe ineffective dosages of these
medications, they do not work and lead patients to discontinue these medications preemptively.
Duloxetine and pregabalin have minor side effects that many patients are unable to
tolerate. They may discontinue these medications early due to these side effects. Having patients
use the lowest recommended dosage for both medications may lessen the chance of developing
adverse drug reactions as the side effects increase with an increase in dosage.
Pregabalin was found to improve patient’s sleep in addition to DPNP in one study. This
secondary component might improve the patient’s overall well-being, quality of life, and level of
functioning. Further studies would be warranted.
One study found that both medications have different effects on neuropathic pain
components. The examination of a patient’s unique sensory profiles in response to pain could
provide more accurate information for future treatment options. This finding would also benefit
from replication.
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